We are pleased to announce our FY23 Financial Results. Please see our release for corporate updates - including an update to the primary efficacy endpoint data for the PACIFIC Study, which show further improvement in seizure reductions in this study. bit.ly/3PkLjap

Thank you to the San Diego Business Journal and last night's sponsors for honoring Brandi Roberts at the CFO of the Year Awards! Brandi has been instrumental in the success of Longboard over the past three years and we are very proud of her for this accomplishment. #SanDiego #CFO

Today we presented late-breaking data from the PACIFIC Study at the American Academy of Neurology (AAN) 2024 Annual Meeting #AANAM in both a podium presentation and an emerging science poster session. Our poster can be viewed here on our website. bit.ly/43ZdFwN

Thank you to our employees who participated in the Walk ‘n’ Wheel for #LGS Research and the Epilepsy Foundation of America Sharon's Ride.Run.Walk. We are grateful to be part of such an amazing community and proud of our work in the #DEE space! LGS Foundation

Honored to have our own Kevin Lind, President & CEO, recognized as a finalist in the Entrepreneur Of The Year® 2024 Pacific Southwest program. #EOYUS #EOYPACSW lnkd.in/gD6sJPBS

Amazing time this week collaborating with the top opinion leaders in Europe at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII)! Thank you to the International League Against Epilepsy for including us in this terrific meeting. #EILATXVII $LBPH

We look forward to attending #BIO2024 in our hometown of San Diego next week! If you are interested in meeting with the $LBPH team, please contact us at [email protected].

If you are attending hashtag #BIO2024 we invite you to attend a panel featuring Steven Spector, Longboard’s EVP, Head of Business Development and General Counsel, and other esteemed speakers, for a discussion regarding the biotech IPO landscape. bit.ly/4aDagW7

Great week in Boston at The Association of Bioscience Financial Officers 2024 Conference! Brandi Roberts, Longboard's CFO, participated in the CFO Best Practices panel. #ABFO #ABFO2024

Today, we announced positive interim results from our ongoing 52-week open-label extension (OLE) of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with #DEEs. Additional detail can be found in our press release bit.ly/4efEgKU

Today, we raise awareness for CDKL5 Deficiency Disorder, a rare genetic condition causing developmental and epileptic encephalopathy and early-onset seizures. #CDKL5 #CDKL5Awareness Thank you to the CDKL5 - IFCR for hosting us at your conference last week!

Thank you to Life Science Cares San Diego and our Longboard team members that volunteered at Feeding San Diego last week. Great teamwork for a great cause!

We’re proud to stand with the Dravet syndrome community, especially today for the International Dravet Syndrome Awareness Day. This weekend we had the opportunity to meet with families and Dravet warriors at the Dravet Syndrome Foundation Family & Professional Conference!

The U.S. FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with DEEs for patients two years of age or older. We are excited for the potential implications for the DEE community! bit.ly/3XLGnQX

This week we participated in the LGS Foundation 9th International Family & Professional Conference! Our team appreciated spending time with the inspiring individuals living with LGS & their loved ones. Thank you to LGSF & the community for involving us in this important event!

This weekend our team attended the CACNA1A Foundation Research Roundtable and Creating Connections Community Conference. Thank you to the CACNA1A Foundation for including us in this incredible event!

Thank you to our amazing summer interns who are supporting efforts and gaining key insights across the organization! We hope you are enjoying the experience as much as we love having you here. Cheers to a bright future!

We’re grateful to the AngelmanSyndromeFdn & Dup15q Alliance for the opportunity to share our PACIFIC Study data at their joint research symposium last week. Witnessing their resilience and commitment to advance treatments for their community is truly inspiring. Thank you for including us!

We were honored to participate in panels at the FamilieSCN2A Foundation 2024 Research Roundtable last week! It is so inspiring spending time at these events and we value the interactions with the families, caregivers and HCPs.

We are pleased to be chosen as one of the Best Places to Work in San Diego - Thank you to San Diego Business Journal for this honor! We foster a culture that is collaborative & inclusive, and are driven by our mission to develop novel, transformative medicines for neurological conditions.